Islatravir diphosphate – CAS 950913-57-2


Islatravir diphosphate  is synthesised by Santiago Lab (Prague, Czech Republic). All products are lyophilized and can easily sustain the shipment oversee.

Purity (LC-MS)


Package contents

Islatravir diphosphate triethylammonium salt

This compound is for research use only. We do not sell to patients.
1 mg

In stock

5 mg

In stock


Islatravir diphosphate – CAS 950913-57-2


CAS: 950913-57-2

IUPAC Name: ((2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl)methyl trihydrogen diphosphate

Other names: EFdA-DP, MK-8591-DP

Molecular weight: 453.22 g/mol, 

Molecular formula: C12H14FN5O9P2


Islatravir diphosphate is synthesised by Santiago Lab (Prague, Czech Republic) and it is a metabolite of Islatravir. Islatravir (EFdA, or MK-8591) is an investigational drug for the treatment of HIV infection developed by company Merck. It is classified as a nucleoside reverse transcriptase translocation inhibitor (NRTTI).  Islatravir has activity against HIV in animal models and is being studied clinically for HIV treatment and prophylaxis. Islatravir is a nucleoside analogue reverse transcriptase translocation inhibitor that, unlike other such inhibitors, inhibits HIV through multiple mechanisms, providing rapid suppression of the virus, when tested in macaques and mice.  Islatravir inhibits HIV reverse transcriptase but has a different mechanism of action with respect to all other approved NRTIs because of its unique structural features: a 3’-hydroxyl group makes this nucleotide a translocation inhibitor rather than a chain terminator. Introducing a 4’-ethynyl group enhances the selectivity towards the HIV reverse transcriptase. Similarly to other nucleoside antiviral drugs, Islatravir is first transformed to islatravir-5’-triphosphate (ISL-TP), which is the biologically active form of Islatravir. When ITP is incorporated into forming DNA strand by the reverse transcriptase, it acts as a chain terminator by preventing the translocation.

Based on its unique properties, Merck is currently developing a sub-dermal implant for the long-term release of Islatravir. This implant is now under clinical evaluation and is likely to cause a revolution in HIV treatment. You can find more information about Islatravir in our article.


Chemicals are distributed worldwide

Buy Islatravir  now, get your order in 48 hours
  • Shipping through DHL in 48 hours. We can also arrange shipping on dry ice.
  • All compounds are safely and rigorously packed
  • We are sending the invoice the same day as the shipment
  • We can modify the invoice for the academic institution so that the order can be paid from grants

1. Kawamoto, A; Kodama, E; Sarafianos, SG; Sakagami, Y; Kohgo, S; Kitano, K; Ashida, N; Iwai, Y; Hayakawa, H; Nakata, H; Mitsuya, H; Arnold, E; Matsuoka, M (2008). "2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants". The International Journal of Biochemistry & Cell Biology. 40 (11): 2410–20. doi:10.1016/j.biocel.2008.04.007. PMID 18487070.
2. Roy M. Gulick (2018). "Investigational Antiretroviral Drugs: What is Coming Down the Pipeline". Top Antivir Med. 25 (4): 127–132. PMC 5935216. PMID 29689540.

Related products: